Metalloproteinase oligopeptides and their therapeutic use

Abstract

The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides, SEQ ID 5-SEQ ID 21. These oligopeptides are bound to antibodies to create an immune response in the subject mammal against the matrix metalloproteinases of various diseases. This is a means of therapeutic intervention against the disease spread created by the matrix metalloproteinases. Further use of these oligopeptide-antibody responses can be extended to any and all diseases that use the matrix metalloproteinases to aid in their pathogenicity.

What is claimed is: 
     
         1 . A method, comprising:
 identifying an oligopeptide sequence for a matrix metalloproteinase expressed in a specific disease;   synthesizing the oligopeptide sequence for the matrix metalloproteinase, wherein the oligopeptide sequence of the matrix metalloproteinase is at least one of SEQ ID 5 to 21 and combination thereof;   formulating a therapeutically effective amount of a treatment composition using the oligopeptide sequence of the matrix metalloproteinase; and   administering the treatment composition of the oligopeptide sequence to treat a mammal having the specific disease exhibiting an over expression of the matrix metalloproteinase.   
     
     
         2 . The method of  claim 1 , wherein administering is injecting the treatment composition as a vaccine to the mammal for treating the specific disease. 
     
     
         3 . The method of  claim 2 , wherein the specific disease is at least one of neoplastic disease, inflammatory disease, coronary artery disease, occlusive cardiovascular disease, degenerative disease and infectious disease. 
     
     
         4 . The method of  claim 3 , wherein the specific disease is cancer. 
     
     
         5 . The method of  claim 1 , further comprising:
 formulating the therapeutically effective amount of the treatment composition using a SEQ ID 5 to 21 oligopeptide sequence of the matrix metalloproteinase;   administering the treatment composition comprising of at least one of the SEQ ID 5 to 21 and combination thereof for treating the mammal; and   generating an immune response in a mammal.   
     
     
         6 . The method of  claim 1 , wherein the therapeutically effective amount is administered using at least one of a non-invasive peroral, topical, enteral, transmucosal, targeted delivery, sustained release delivery and parenteral method. 
     
     
         7 . The method of  claim 6 , wherein the therapeutically effective amount is the parenteral used as a vaccine. 
     
     
         8 . A composition, comprising:
 a matrix metalloproteinase oligopeptide; and   a pharmaceutically acceptable excipient.   
     
     
         9 . The composition of  claim 8 , further comprising:
 a carrier protein;   an additive to enhance the chemical stability; and   an adjuvant to increase the immunogenicity of the composition.   
     
     
         10 . The composition of  claim 8 , wherein the matrix metalloproteinase oligopeptide is at least one of SEQ ID 5 to 21 and combination thereof. 
     
     
         11 . The composition of  claim 8 , wherein the matrix metalloproteinase oligopeptide is at least one of linear and circular in shape. 
     
     
         12 . A method, comprising:
 measuring the level of expression of a matrix metalloproteinase in a specific species having a specific disease; and   identifying an oligopeptide sequence for a matrix metalloproteinase expressed in the specific disease to determine a treatment method.   
     
     
         13 . The method of  claim 12 , further comprising:
 synthesizing the oligopeptide sequence of the matrix metalloproteinase;   formulating a treatment composition for producing a therapeutically effective amount of the oligopeptide sequence of the matrix metalloproteinase; and   injecting the treatment composition as a vaccine to the specific species for treating the specific disease having an over expression of a matrix metalloproteinase.   
     
     
         14 . The method of  claim 13 , further comprising:
 reducing a tumor size by treating the specific species having the tumor, wherein the specific disease is cancer, wherein the specific species are at least one of a mammal and a non mammal.   
     
     
         15 . The method of  claim 14 , wherein the treatment composition is the injected directly into the tumor. 
     
     
         16 . The method of  claim 13 , wherein the oligopeptide sequence for the matrix metalloproteinase is at least one of a SEQ ID 5 to 21 and combination thereof. 
     
     
         17 . The method of  claim 14 , further comprising:
 coupling the sequence of matrix metalloproteinase with a hapten to enhance the immune response as the vaccine.   
     
     
         18 . The method of  claim 17 , further comprising;
 formulating the therapeutically effective amount of the treatment composition using a peptidomimetic sequence of the matrix metalloproteinase; and   administering the formula comprising of at least one of the matrix metalloproteinase SEQ ID 5 to 21 and combination thereof as the treatment composition for treating the specific species.   
     
     
         19 . The method of  claim 18 , further comprising:
 reducing the activity of at least one of a matrix metalloproteinase-2 and a matrix metalloproteinase-9 using a vaccine comprising at least one of a oligopeptide sequence of SEQ ID 5 to 21 and combination thereof to induce an immune response.